Surgery or radiation for locally advanced pancreatic cancer after chemotherapy
This study compares two treatments for locally advanced pancreatic cancer that has responded well to initial chemotherapy: surgery to remove the tumor or a precise, non-invasive radiation therapy called SABR. The goal is to see which approach offers better control of the cancer and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your pancreatic cancer is locally advanced (not spread to other organs) and confirmed by biopsy or strong imaging evidence.
- You have completed at least 3 months of chemotherapy and the tumor has not grown, and you are well enough (performance status 0-1).
- Your CA19-9 tumor marker level dropped by more than 40% and is now below 300 U/mL (or you have specific radiology or other marker results).
- A surgeon and radiation team believe both surgery and radiation are technically possible for you.
- You do not have cancer spread (metastases) and you have not had any prior radiation to this area, except for a single dose for bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether surgery can help people with a certain type of pancreatic cancer that is locally advanced but not yet spread. You may join if your cancer has shrunk or stayed stable after at least 4 months of chemotherapy and your medical team thinks surgery is possible.
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Pancreatic Carcinoma (LAPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.